Anonymous
Guest
Anonymous
Guest
Let's watch poor Floootsie sit
Cursing the government
For not reimbursing his
VPAK
at the rate
he sees fit....
Cursing the government
For not reimbursing his
VPAK
at the rate
he sees fit....
At the very minimum; more likely 65-85 % gone.51% cuts
Scripts are increasing so layoffs will not be needed. Keep the faith and keep on selling!
My DM strongly feels that this Fri ER will report VPak 2q15 sales +$750M, which will exceed the $3B run rate. Hitting this number will reinforce to replace the loser reps who left.
Message to all negative posters: Eat S**T! We are kicking butt! "In Hep-C, we estimate that AbbVie can get 13-18% market share, varying by region. We now forecast WW Hep-C sales of $2.8Bn in 2016 (up from $2.5Bn) and $2.6Bn in 2017 (up from $2.3Bn) because we believe that after the TURQUOISE-III study, Viekira is more competitive in GT-1b patients."
I agree, can't wait to see earnings this Friday. VPak will blow past revenue estimates of $750M & market share +15%.
Message to all negative posters: Eat S**T! We are kicking butt! "In Hep-C, we estimate that AbbVie can get 13-18% market share, varying by region. We now forecast WW Hep-C sales of $2.8Bn in 2016 (up from $2.5Bn) and $2.6Bn in 2017 (up from $2.3Bn) because we believe that after the TURQUOISE-III study, Viekira is more competitive in GT-1b patients."
"My DM told me", so stupid to think a DM has more information than a rep. We can read press releases, follow companies, and figure things out for ourselves. Ever heard of the Internet? "My DM told me" is a fake post from management stuck in 1990 when we had to use payphones to check voice mail. What a retro, back dated, authoritarian, Abbvie has become. Sad for you guys that are still there, no forward thinking leadership. The folks in charge don't trust their people to make good business decisions , i.e. Just do what we tell you. Terrible, toxic culture. Need to scrap leadership and start over.
Message to all negative posters: Eat S**T! We are kicking butt! "In Hep-C, we estimate that AbbVie can get 13-18% market share, varying by region. We now forecast WW Hep-C sales of $2.8Bn in 2016 (up from $2.5Bn) and $2.6Bn in 2017 (up from $2.3Bn) because we believe that after the TURQUOISE-III study, Viekira is more competitive in GT-1b patients."